A record of what Sunil Subramaniam said publicly, with the source. Not advice.
Pending — not yet graded
“Bullish on the Pharma sector, seeing a rapid growth opportunity for India due to potential tariffs on Chinese API producers under Trumponomics. The sector is also expected to benefit from currency depreciation, making it a key focus from an external orientation perspective.”
Nifty PharmaBullishCalled 11 Feb 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Sunil Subramaniam’s full track record